Quanxin Bio-B (02509) and CALDERA THERAPEUTICS have signed an exclusive licensing agreement for preclinical bispecific antibody programs targeting TL1A and IL-17

Zhitongcaijing · 4d ago

According to the Zhitong Finance App, Quanxin Bio-B (02509) announced that on November 5, 2026, the company and Caldera Therapeutics, Inc. signed an external licensing agreement for a pre-clinical bispecific antibody project targeting TL1a and IL-17 (specifically IL-17A and IL-17A/F).

Under the terms and conditions of the license agreement, Caldera Therapeutics is granted the exclusive, royalty-payable, transferable and sublicensable right to research, develop, register, manufacture and commercialize candidate products derived from the licensed project on a global scale. In return, the company or its designated subsidiary will be entitled to receive a one-time, non-refundable and non-deductible down payment of $30 million. Subject to reaching certain clinical development, regulatory and commercial milestones, the Group can also collect additional payments of up to US$750 million. The Group will also be entitled to collect tiered royalties on net sales within a specified period after the first commercial sale of products originating from the licensed project.